Skip to main content
OpenTrials
Completed

NCT Number: NCT05146206

Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray

The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Allergic Rhinitis Behavior Health Behavior Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Nose Diseases Otorhinolaryngologic Diseases Patient Preference Patient Satisfaction Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis, Allergic Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Community and Patient Preference Research Pty Ltd

Sydney, New South Wales, 2000, Australia

About this study

The study seeks to understand patients' satisfaction and importance of treatment attributes for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).

To directly compare patient satisfaction with 2 different Allergic Rhinitis nasal sprays, an observational, cross-sectional study design with 2 independent samples was chosen. Participants will complete an online survey involving a Best-Worst scaling (BWS) task to determine satisfaction and importance index for sensory attributes.

The suggested treatment attributes are informed by a range of previous studies, including those conducted by Meltzer et al 2005 and Price et al 2020, and methodology from CaPPRe's own work in developing indices for importance and satisfaction of treatment attributes using BWS.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be offered the opportunity to participate in the study:

  • Patients above 18 years old
  • Fluent in English
  • Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and currently using treatment
  • Willing and able to provide consent to participate

Exclusion criteria

  • Have reported a loss of taste and/or smell related to COVID-19 (or other medical condition)
  • Are employed by a pharmaceutical company (to avoid conflict of interest)
  • Are employed by a vaccine company (to avoid conflict of interest)
  • Do not have access to the internet (to ensure validity of the data)
  • Are unable to read and understand English (to ensure validity of the data)

Treatment and study plan

Observational

Other

In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.

Primary outcomes

  1. Overall Best-Worst Scaling Task Index Score (Treatment Satisfaction Index Score)

    Time frame: Cross-sectional - through study completion, an average of 3 months

    The primary study endpoint is the overall index score from the Best Worst Scaling exercise, to reflect satisfaction and importance of treatment attributes of the RYALTRIS® and DYMISTA® nasal spray.

    Index scores from the Best Worst Scaling exercise range from 0 to 100, with higher scores indicating higher satisfaction of treatment attributes.

Secondary outcomes

  1. Rescaled Scores From Best-Worst Scaling Task

    Time frame: Cross-sectional - through study completion, an average of 3 months

    Secondary study endpoints were the rescaled Best Worst Scaling domain scores from the Best Worst Scaling exercise (i.e., scores for each of the domains on satisfaction and importance).

    Rescaled Best-Worst Scaling domain scores range from 0 to 10 and represent the satisfaction and importance of each domain. Higher satisfaction rescaled scores indicate higher satisfaction on a treatment attribute. Higher importance rescaled scores indicate higher importance of the treatment attribute. Higher rescaled satisfaction and importance scores suggest a better outcome since participants are satisfied and more likely to adhere to their current treatment.

Sponsors and collaborators

Lead sponsor

Community and Patient Preference Research Pty Ltd

Industry

Collaborators

  • Glenmark Pharmaceuticals S.A.
  • Seqirus

Registry information

Official study title

Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments for Allergic Rhinitis

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Dec 6, 2021
Registry last updated
Apr 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.